Profile data is unavailable for this security.
About the company
Insmed Incorporated is a global biopharmaceutical company. It is advancing a diverse range of approved and mid- to late-stage investigational medicines and drug discovery. Its advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. Its pre-clinical research programs encompass a range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Its first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib, TPIP, and INS1201 and pre-clinical research programs. Its INS1148 is an investigational monoclonal antibody.
- Revenue in USD (TTM)447.02m
- Net income in USD-1.18bn
- Incorporated1999
- Employees1.27k
- LocationInsmed Inc700 Us Highway 202/206BRIDGEWATER 08807United StatesUSA
- Phone+1 (908) 977-9900
- Websitehttps://insmed.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revolution Medicines Inc | 0.00 | -960.98m | 18.62bn | 809.00 | -- | 11.44 | -- | -- | -5.18 | -5.18 | 0.00 | 8.42 | 0.00 | -- | -- | 0.00 | -47.87 | -28.38 | -52.53 | -30.68 | -- | -- | -- | -1,324.37 | -- | -- | 0.1384 | -- | -100.00 | -- | -37.52 | -- | 31.83 | -- |
| Exact Sciences Corp | 3.25bn | -207.95m | 19.71bn | 7.10k | -- | 8.20 | 1,437.96 | 6.07 | -1.10 | -1.10 | 17.21 | 12.58 | 0.5509 | 5.99 | 11.86 | 457,322.50 | -3.53 | -8.66 | -3.99 | -9.54 | 69.69 | 70.20 | -6.40 | -21.53 | 2.17 | -- | 0.4935 | -- | 17.69 | 16.84 | 79.79 | -- | -15.13 | -- |
| Iqvia Holdings Inc | 16.31bn | 1.36bn | 28.31bn | 91.00k | 21.25 | 4.35 | 11.40 | 1.74 | 7.86 | 7.86 | 93.98 | 38.34 | 0.5739 | -- | 4.94 | -- | 4.71 | 4.69 | 6.47 | 6.14 | 33.29 | 34.29 | 8.21 | 8.18 | -- | 3.36 | 0.7034 | -- | 5.87 | 7.50 | -0.9468 | 37.27 | -0.4257 | -- |
| Insmed Inc | 447.02m | -1.18bn | 31.72bn | 1.27k | -- | 33.44 | -- | 70.97 | -6.18 | -6.18 | 2.35 | 4.45 | 0.2026 | 0.9558 | 8.31 | 351,708.90 | -53.64 | -44.83 | -63.35 | -51.79 | 76.54 | 77.08 | -264.83 | -226.78 | 4.34 | -44.87 | 0.4351 | -- | 19.17 | 21.66 | -21.91 | -- | -12.30 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Darwin Global Management Ltd.as of 30 Sep 2025 | 20.46m | 9.59% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 19.46m | 9.12% |
| JPMorgan Investment Management, Inc.as of 31 Dec 2025 | 19.21m | 9.01% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 11.50m | 5.39% |
| Fidelity Management & Research Co. LLCas of 30 Sep 2025 | 8.93m | 4.19% |
| T. Rowe Price Associates, Inc. (IM)as of 30 Sep 2025 | 6.76m | 3.17% |
| Baker Bros. Advisors LPas of 30 Sep 2025 | 6.70m | 3.14% |
| D. E. Shaw & Co. LPas of 30 Sep 2025 | 5.66m | 2.65% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 5.20m | 2.44% |
| Capital Research & Management Co. (International Investors)as of 31 Dec 2025 | 5.15m | 2.42% |
